Drugs / nurulimab
nurulimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03472027 | Oct 2017 → Sep 2018 | melanoma | Biocad | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05751928 | Apr 2023 → Jan 2027 expected | cutaneous melanoma | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05732805 | Aug 2022 → Jun 2024 overdue | cutaneous melanoma, metastatic melanoma | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nurulimab | “Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with...” NCT05732805 ↗1“BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting” NCT05751928 ↗ |
| Known as | Anti-ctla4 mab (biocad) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594529 ↗ |
| Known as | BCD-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03472027 ↗ |
| Action | Inhibit | “anti-CTLA4 agent” NCT05751928 ↗ |
| Modality | Monoclonal antibody | “Anti-CTLA-4 monoclonal antibody” NCT03472027 ↗ |
| Route | Intravenous | “Anti-CTLA-4 monoclonal antibody, IV infusion” NCT03472027 ↗ |